PALO ALTO, CA February 26, 2024 — Lucence announced its receipt of confirmation that Medicare coverage for its LiquidHALLMARK® liquid biopsy test applies for patients with all stages of advanced solid tumors. This confirmation marks a significant milestone in promoting access to personalized oncology care on a broader scale.
Medicare Coverage Expansion
Dr. Min-Han Tan, Lucence’s Founding CEO, highlighted the importance of this confirmation of comprehensive Medicare coverage, stating it “broadens the accessibility of LiquidHALLMARK® to a wider patient demographic, reinforcing our commitment to personalized cancer care.”
Study Findings
Further establishing LiquidHALLMARK®’s impact, LIQUIK-01, a prospective multicenter study recently reported at the 2023 North America Conference on Lung Cancer (NACLC) [1] that LiquidHALLMARK® detected more tissue-confirmed guideline-recommended biomarkers than an FDA-approved liquid biopsy test in 151 patients with metastatic non-squamous non-small cell lung cancer (NSCLC). The research demonstrated LiquidHALLMARK®’s sensitive performance in identifying key NSCLC biomarkers with 93.2-100% concordance with tissue NGS across 9 biomarkers. LiquidHALLMARK® ctDNA testing detected 15.6% (7/45) more G9 biomarkers than the FDA-approved liquid biopsy test, a figure that increased to 20% (9/45) with the inclusion of 2 additional gene fusions identified only by ctRNA testing.
[1] Samol et al. (2023 Dec 1-3). LiquidHallmark detects more tissue-confirmed guideline-recommended biomarkers in lung cancer: prospective multicenter study [Poster]. 2023 North American Conference on Lung Cancer, Chicago, IL.
About Lucence
Lucence is a precision oncology company focused on bringing clarity to cancer care. Our ultrasensitive liquid biopsy tests are based on proprietary AmpliMark™ sequencing technology and data analytics for earlier detection and effective treatment. Lucence operates twin CLIA-licensed, CAP-accredited laboratories in California and Singapore. For more information, visit www.lucence.com.